Autres langues TriSalus Life Sciences, Inc.

Actions

TLSI

US89680M1018

Cours en clôture Nasdaq Autres places de cotation 00:00:00 12/07/2024			Varia. 5j.	Varia. 1 janv.
5,4 ^USD	+0,75 %		-0,92 %	-36,09 %

03/06	TriSalus Life Sciences, Inc. présente les données cliniques de l'essai de phase 1b Perio-02	CI
30/05	TRISALUS LIFE SCIENCES, INC. : Canaccord Genuity toujours positif	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation	01/07
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants	26/06
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting	03/06
TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial	03/06
TriSalus Life Sciences Launches Warrant Exchange Offer	24/05
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants	24/05
TriSalus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Earnings Flash (TLSI) TRISALUS LIFE SCIENCES Posts Q1 Revenue $6.5M, vs. Street Est of $5.9M	15/05
TriSalus Reports Q1 2024 Financial Results and Business Update	15/05
TriSalus Life Sciences, Inc. Provides Sales Guidance for the Full Year of 2024	15/05
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors	07/05
TriSalus Life Sciences, Inc. Appoints Liselotte Hyveled to Its Board of Directors	07/05
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call	06/05
TriSalus Life Sciences Obtains $50 Million Debt Facility	01/05
Trisalus Life Sciences, Inc. and Trisalus Operating Life Sciences, Inc. Enters into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP	30/04
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives	30/04
TriSalus Life Sciences, Inc. announced that it expects to receive $50 million in funding from OrbiMed Advisors LLC	30/04
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update	01/04
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
TriSalus Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	01/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TriSalus Life Sciences, Inc.

Actions

TLSI

US89680M1018

Autres langues

Filtres